Global Oncology Imaging AI Market Pulse 2025–2032 Size, Mix and Momentum

The global Oncology Imaging AI market is forecast to expand from US$604.7M in 2023 to US$7.74B by 2032 (32.7% CAGR), driven by increasing adoption across cancer screening, diagnostic imaging workflows, treatment planning (including RT), and response assessment.

Global Oncology Imaging AI Market Pulse 2025–2032: Size, Mix & Momentum provides a world-market forecast and segmentation view of AI in oncology imaging across regions, modalities (CT, mammography/DBT, MRI, PET/Nuclear, ultrasound), tumor sites, clinical applications, pathway stages, end-use settings, and revenue streams. The report is designed for corporate strategy, product, commercial, and investment teams who need a clean global sizing reference and a structured view of where growth concentrates.

A key differentiator is the report’s Mix & Momentum framework—pairing 2032 market-size mix (with over/under indexing versus the global benchmark) with dollar-lift growth contribution views. These matrices enable readers to identify “big pools” versus “fast pools,” prioritize the highest-leverage tumor-site and modality intersections, and understand how monetization shifts across software, services, and cloud/usage-based (PPU) models."

"Competitive Snapshot (commercial reality, not market shares)

This Global Pulse focuses on how the market is captured—not vendor-by-vendor market shares. The report highlights the commercial rails that shape winners and pricing power across segments:

OEM bundling and “default attach” economics in high-volume modalities and screening lanes
Enterprise contracting and governance requirements in IDNs and cancer networks
Marketplace/platform distribution that reduces deployment friction for multi-vendor portfolios
Teleradiology and centralized reading hubs as catalysts for usage-based pricing and standardized QA

The following companies/divisions have been mentioned (not profiled): Aidoc; AIQ Solutions; Annalise.ai; Arterys; Bayer; Blackford; Calantic; Canon Medical; CARPL.ai; DeepHealth; Deepwise; Densitas; EXINI Diagnostics; Fujifilm; GE HealthCare; Hermes Medical Solutions; Hologic; Imbio; Incepto; Kheiron; Koios Medical; Lantheus; Lunit; Median Technologies; MIM Software; Mindray; Mirada Medical; MVision AI; Nuance; Oxipit; Perspectum; Philips; Ping An Healthcare; Quibim; Qure.ai; Rad AI; RadNet; RaySearch; Riverain; ScreenPoint; Sectra; Segami; Siemens Healthineers; Subtle Medical; Tempus; TheraPanacea; United Imaging; Vara; Varian

Questions Answered

Inside this report, readers gain immediate answers to questions such as:

Which regions are over- or under-indexed in specific modalities or pathway stages versus the global mix?
Where is the largest dollar lift coming from—by modality, tumor site, pathway stage, and revenue stream?
Which tumor-site × modality combinations create the most incremental dollars (e.g., breast × X-ray/DR, lung × CT, prostate × MRI)?
Where are cloud/PPU models structurally advantaged versus traditional licensing?

Why This Report

Global Oncology Imaging AI Market Pulse 2025–2032 is built for teams that need high-confidence sizing plus practical segmentation—the combination required to make real decisions:

Portfolio and roadmap decisions: Which modalities and tumor sites are worth sustained investment?
Market entry and sequencing: Where do you start (big pools) vs where do you place selective bets (fast pools)?
Commercial strategy: How will revenue models evolve (license vs service vs usage), and where will pricing compress vs hold?
Investor and diligence workflows: Which growth narratives are supported by global mix/momentum patterns rather than anecdote?

Report Stats

No. of Pages: 111
No. of Figures: 30
Companies/Divisions Mentioned (not profiled): ~45 Show more